Elevian, Inc
Elevian, Inc., based in Menlo Park, CA, is dedicated to developing innovative medicines that facilitate recovery and regeneration, particularly in the aftermath of stroke—a leading cause of long-term disability and death worldwide. Their lead program focuses on a recombinant protein known as rGDF11, which has shown promise in enhancing recovery after both ischemic and hemorrhagic strokes by promoting neovascularization, neurogenesis, and reducing inflammation.
In addition to stroke, Elevian's rGDF11 has demonstrated potential benefits in treating various aging-related diseases, making it a versatile candidate for addressing multiple health challenges associated with aging. The company's commitment to kindness, diligence, openness, community, responsibility, and enjoyment underscores its mission to transform the future of medicine.
Generated from the website
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.